Skip to main content
×
Home

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report

  • A. A. Nierenberg (a1), M. M. Husain (a2), M. H. Trivedi (a2), M. Fava (a1), D. Warden (a2), S. R. Wisniewski (a3), S. Miyahara (a3) and A. J. Rush (a4)...
Abstract
Background

Many patients with major depressive disorder (MDD) who experience full symptomatic remission after antidepressant treatment still have residual depressive symptoms. We describe the types and frequency of residual depressive symptoms and their relationship to subsequent depressive relapse after treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Method

Participants in primary (n=18) and psychiatric (n=23) practice settings were openly treated with citalopram using measurement-based care for up to 14 weeks and follow-up for up to 1 year. We assessed 943 (32.8% of 2876) participants who met criteria for remission to determine the proportions with individual residual symptoms and any of the nine DSM-IV criterion symptom domains to define a major depressive episode. At each visit, the 16-item Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR16) and the self-report Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale were used to assessed depressive symptoms and side-effects respectively.

Results

More than 90% of remitters had at least one residual depressive symptom (median=3). The most common were weight increase (71.3%) and mid-nocturnal insomnia (54.9%). The most common residual symptom domains were sleep disturbance (71.7%) and appetite/weight disturbance (35.9%). Those who remitted before 6 weeks had fewer residual symptoms at study exit than did later remitters. Residual sleep disturbance did not predict relapse during follow-up. Having a greater number of residual symptom domains was associated with a higher probability of relapse.

Conclusions

Patients with remission of MDD after treatment with citalopram continue to experience selected residual depressive symptoms, which increase the risk of relapse.

Copyright
Corresponding author
*Address for correspondence: A. A. Nierenberg, M.D., Massachusetts General Hospital, Suite 580, 50 Staniford Street, Boston, MA 02114, USA. (Email: anierenberg@partners.org)
References
Hide All
Bockting C, Spinhoven P, Koeter M, Wouters L, Schene A; Depression Evaluation Longitudinal Therapy Assessment (DELTA) Study Group (2006). Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. Journal of Clinical Psychiatry 67, 747755.
Carney CE, Segal ZV, Edinger JD, Krystal AD (2007). A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Journal of Clinical Psychiatry 68, 254260.
DeBattista C, Doghramji K, Menza M, Rosenthal M, Fieve R (2003). Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 10571064.
Fava G, Ruini C, Belaise C (2007). The concept of recovery in major depression. Psychological Medicine 37, 307317.
Fava GA, Fabbri S, Sonino N (2002). Residual symptoms in depression: an emerging therapeutic target. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26, 10191027.
Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America 26, 457494.
Fava M, Thase ME, DeBattista C (2005). A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry 66, 8593.
Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 5661.
Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278296.
Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998 a). Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders 50, 97–108.
Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB (1998 b). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry 55, 694700.
Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T, Takahashi K (2003). Time to recurrence after recovery from major depressive episodes and its predictors. Psychological Medicine 33, 839845.
Kennedy N, Paykel E (2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135144.
Leon AC (2007). The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. American Journal of Psychiatry 164, 17861789.
Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Stajic M, Piper TM, Galea S (2007). Antidepressants in adult suicides in New York City: 2001–2004. Journal of Clinical Psychiatry 68, 13991403.
Mintz J, Mintz LI, Arruda MJ, Hwang SS (1992). Treatments of depression and the functional capacity to work. Archives of General Psychiatry 49, 761768.
Mojtabai R (2001). Residual symptoms and impairment in major depression in the community. American Journal of Psychiatry 158, 16451651.
Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, Rosenbaum JF, Fava M (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry 60, 221225.
Nierenberg AA, Wright EC (1999). Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry 60, 7–11.
Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M (2006 a). An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biological Psychiatry 59, 493501.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G (2004). Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Controlled Clinical Trials 25, 119142.
Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF (2006 b). Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 31, 18411853.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573583.
Simon GE (2006). How can we know whether antidepressants increase suicide risk? American Journal of Psychiatry 163, 18611863.
Stahl SM, Zhang LS, Damatarca C, Grady M (2003). Brain-circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Journal of Clinical Psychiatry 64, 6–17.
Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ (2006). Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectrums 11, 93–102.
Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB, Witte B, Kashner TM (2004). The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine 34, 7382.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 2840.
Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA, for the STAR*D Investigators (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice 12, 7179.
Zimmerman M, Posternak MA, Chelminski I (2007). Heterogeneity among depressed outpatients considered to be in remission. Comprehensive Psychiatry 48, 113117.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 11
Total number of PDF views: 224 *
Loading metrics...

Abstract views

Total abstract views: 991 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th November 2017. This data will be updated every 24 hours.